

09/806568

532 Rec'd PCT/PTO 02 APR 2001
PATENT
0020-4841P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: MORIKAWA, Wataru et al. Conf.:
Appl. No.: New Group:
Filed: April 2, 2001 Examiner:
For: ENZYME PRODUCING PLASMA PROTEIN FRAGMENT
HAVING INHIBITORY ACTIVITY TO METASTASIS
AND GROWTH OF CANCER AND PLASMA PROTEIN
FRAGMENT PRODUCED BY FRAGMENTATION BY
SAID ENZYME

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION CONCURRENT WITH THE
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents
Washington, DC 20231

April 2, 2001

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- ☐ Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☒ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should be forwarded from the International Search Authority. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☐ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached patents, publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☒ **ENGLISH LANGUAGE SEARCH REPORT**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEES


This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. \$ 1.16 or under \$ 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Marc S. Weiner, #32,181

MSW/cqc
0020-4841P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Enclosures: ☒ Form PTO-1449(s)
☐ Documents
☐ Foreign Search Report
☐ Fee
☒ Other: International Search Report

(Rev. 01/22/01)

APPLICATION NO. **97806568**

CONF. NO.

GROUP	1642
-------	------

[illegible][illegible]

	Gately et al., <i>CancerRes.</i> , Vol. 56, No. 21, pp. 4887-4890 (1996)
	Soffa et al., <i>J. Clin. Invest.</i> , Vol. 96, No. 6, pp. 2593-2600 (1995)
	O'Reilly et al., <i>Nat. Med.</i> , Vol. 2. No. 6, pp. 689-692 (1996)
	O'Reilly et al., <i>Cell</i> , Vol. 79. No. 2, pp. 315-328 (1994)
	Gately et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, No. 20, pp. 10868-72 (1997)
	Briozzo et al., <i>CancerRes.</i> , Vol. 48, No. 13, pp. 3688-3692 (1988)

DATE CONSIDERED

MSW/cqc